NCT06592950View on ClinicalTrials.gov

Patient Preference Study in Type-2 Diabetes Mellitus: Discrete Choice Experiment (DCE) to Support Novo Nordisk's Long-Acting Insulin

CompletedOBSERVATIONAL

Enrollment

513

Participants

Timeline

Start Date

November 2, 2023

Primary Completion Date

April 29, 2024

Study Completion Date

April 29, 2024

Conditions

Type-2 Diabetes Mellitus (T2DM)

Interventions

OTHER

No treatment given

Online survey

OTHER

No treatment given

Interviews

Trial Locations (1)

2860

Novo Nordisk, Søborg

Sponsors

Lead Sponsor

Novo Nordisk A/S

All Listed Sponsors

lead

Novo Nordisk A/S

INDUSTRY

NCT06592950 - Patient Preference Study in Type-2 Diabetes Mellitus: Discrete Choice Experiment (DCE) to Support Novo Nordisk's Long-Acting Insulin | Biotech Hunter | Biotech Hunter